Attacking pathogens through their hosts

被引：26

作者：

Kellam, P ^{[1
]}

机构：

[1] UCL, Div Infect & Immun, Virus Genom & Bioinformat Grp, London W1T 4JF, England

来源：

GENOME BIOLOGY | 2006年 / 7卷 / 01期

关键词：

D O I：

10.1186/gb-2006-7-1-201

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Through understanding the intricacies of host-pathogen interactions, it is now possible to inhibit the growth of microbes, especially viruses, by targeting host-cell proteins and functions. This new antimicrobial strategy has proved effective in the laboratory and in the clinic, and it has great potential for the future.

引用

页数：8

共 42 条

[1] A large-scale RNAi screen in human cells identifies new components of the p53 pathway [J].

Berns, K ;

Hijmans, EM ;

Mullenders, J ;

Brummelkamp, TR ;

Velds, A ;

Heimerikx, M ;

Kerkhoven, RM ;

Madiredjo, M ;

Nijkamp, W ;

Weigelt, B ;

Agami, R ;

Ge, W ;

Cavet, G ;

Linsley, PS ;

Beijersbergen, RL ;

Bernards, R .

NATURE, 2004, 428 (6981) :431-437

[2] In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus [J].

Bordier, BB ;

Ohkanda, J ;

Liu, P ;

Lee, SY ;

Salazar, FH ;

Marion, PL ;

Ohashi, K ;

Meuse, L ;

Kay, MA ;

Casey, JL ;

Sebti, SM ;

Hamilton, AD ;

Glenn, JS .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (03) :407-414

[3] A prenylation inhibitor prevents production of infectious hepatitis delta virus particles [J].

Bordier, BB ;

Marion, PL ;

Ohashi, K ;

Kay, MA ;

Greenberg, HB ;

Casey, JL ;

Glenn, JS .

JOURNAL OF VIROLOGY, 2002, 76 (20) :10465-10472

[4] A selective inhibitor-of eIF2α dephosphorylation protects cells from ER stress [J].

Boyce, M ;

Bryant, KF ;

Jousse, C ;

Long, K ;

Harding, HP ;

Scheuner, D ;

Kaufman, RJ ;

Ma, DW ;

Coen, DM ;

Ron, D ;

Yuan, JY .

SCIENCE, 2005, 307 (5711) :935-939

[5] Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C [J].

Davis, GL ;

Esteban-Mur, R ;

Rustgi, V ;

Hoefs, J ;

Gordon, SC ;

Trepo, C ;

Shiffman, ML ;

Zeuzem, S ;

Craxi, A ;

Ling, MH ;

Albrecht, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1493-1499

[6] Strategies in the design of antiviral drugs [J].

De Clercq, E .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (01) :13-25

[7] Statins inhibit HIV-1 infection by down-regulating Rho activity [J].

del Real, G ;

Jiménez-Baranda, S ;

Mira, E ;

Lacalle, RA ;

Lucas, P ;

Gómez-Moutón, C ;

Alegret, M ;

Peña, JM ;

Rodríguez-Zapata, M ;

Alvarez-Mon, M ;

Martínez-A, C ;

Mañes, S .

JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (04) :541-547

[8] The price of innovation: new estimates of drug development costs [J].

DiMasi, JA ;

Hansen, RW ;

Grabowski, HG .

JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185

[9] Identification of cell surface targets for HIV-1 therapeutics using genetic screens [J].

Dunn, SJ ;

Khan, MH ;

Chan, UA ;

Scearce, RL ;

Melara, CL ;

Paul, AM ;

Sharma, V ;

Bih, FY ;

Holzmayer, TA ;

Luciw, PA ;

Abo, A .

VIROLOGY, 2004, 321 (02) :260-273

[10] Prenylation inhibitors: a novel class of antiviral agents [J].

Einav, S ;

Glenn, JS .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (06) :883-886

← 1 2 3 4 5 →